Multiple Sclerosis Has Doubled in Prevalence in England, But Patients Are Living Longer

The Diagnostic Revolution's Role

The refinement of MRI technology over the study period has been transformative for MS diagnosis. Early MRI systems could detect large lesions in the brain and spinal cord characteristic of established MS, but they often missed smaller or early lesions that are now routinely detectable with modern high-field machines and advanced imaging sequences. The McDonald Criteria — the international diagnostic standards for MS — have also been revised multiple times, incorporating MRI findings in ways that allow diagnosis earlier in the disease course.

The practical result is that patients who in 2000 might have spent years in a diagnostic limbo — experiencing symptoms, undergoing investigations, but not meeting the threshold for a formal MS diagnosis — are now receiving diagnoses more quickly and more reliably. This compression of the diagnostic delay is medically beneficial: earlier diagnosis enables earlier treatment initiation, and the evidence for the benefit of early disease-modifying therapy is now robust. But it also means the prevalence count is capturing a larger share of the true MS population than it previously did.

Survival Improvements: The Treatment Effect

The survival data in the study is striking. Over the two-decade study period, excess mortality associated with MS — the additional mortality risk that MS patients face compared to the general population — declined significantly. This improvement reflects the transformative impact of disease-modifying therapies introduced and expanded in use over this period.

The first approved disease-modifying therapy for MS, interferon beta-1b, entered use in the early 1990s. Since then, the therapeutic landscape has expanded dramatically. There are now more than 20 approved disease-modifying treatments for relapsing forms of MS, ranging from injectable interferons and glatiramer acetate to highly effective oral agents and infused monoclonal antibodies like natalizumab and ocrelizumab that suppress the immune attacks on myelin with a potency that was unimaginable in the early years of the treatment era.

The most effective of these agents have demonstrated the ability to dramatically reduce relapse rates and slow radiological progression on MRI in clinical trials, with real-world outcomes data increasingly confirming that these benefits translate to slowed accumulation of disability and improved quality of life over time. The flip side of this success is that more people are living with MS for longer, which increases prevalence even if incidence were held constant.

Persistent Challenges: Progressive MS and Health Inequalities

The study's positive narrative has important qualifications. Treatment advances have been substantially more successful for relapsing forms of MS than for progressive forms, particularly primary progressive MS. Ocrelizumab became the first therapy approved for primary progressive MS in 2017, offering modest but meaningful benefit in clinical trials, but the treatment gap between relapsing and progressive disease remains substantial.

The study also identified health inequalities in MS outcomes that persist despite overall improvement. Patients from more deprived socioeconomic backgrounds showed worse survival outcomes and less complete access to the most effective therapies, reflecting broader patterns of healthcare inequality in England. Access to specialist neurological care, which is strongly associated with better MS outcomes, varies significantly across geographies in ways that disadvantage patients in areas without nearby tertiary neurology centers.

What the Data Means for Planning MS Care

A doubling of MS prevalence in two decades has direct implications for NHS capacity planning, specialist workforce development, and the budgetary allocation for high-cost disease-modifying therapies. The NHS MS strategy and NICE treatment guidelines will need to account for a growing patient population with increasing years of potential treatment exposure. The cost of the most effective MS therapies — some carrying list prices exceeding £20,000 per patient per year — makes the budgetary dimension of prevalence growth a significant healthcare policy question.

The good news, embedded in the same data that reveals these challenges, is that the growth in MS prevalence is at least partly a story of a healthcare system doing its job: finding cases earlier, treating them more effectively, and keeping patients alive and functional for longer. That is progress, even when it creates its own downstream demands.

This article is based on reporting by Medical Xpress. Read the original article.